Preconception-early childhood telephone-based intervention to optimize growth and development among children in Canada: A Healthy Life Trajectory Initiative (HeLTI-Canada)
| ISRCTN | ISRCTN13308752 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN13308752 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | HLC – 154502 |
| Sponsor | Canadian Institutes of Health Research |
| Funder | Canadian Institutes of Health Research |
- Submission date
- 05/02/2019
- Registration date
- 27/02/2019
- Last edited
- 17/06/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Ongoing
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
Non-communicable diseases (NCDs), including cardiovascular disease, type 2 diabetes mellitus and mental illness (especially depression), are major global contributors to premature death and disability. Cardiometabolic disease -- hypertension, coronary artery disease, and diabetes -- has risen in prevalence globally in parallel with economic development, urbanisation, an obesogenic lifestyle and obesity. Accelerated growth in infancy and early childhood is a strong risk factor for obesity in older children. Childhood overweight and obesity can further negatively impact on child development. In Canada, nearly 1 in 3 children are overweight or obese, about 1 in 4 are not developmentally prepared for school, and 1 in 5 children has a mental health problem. The HeLTI-Canada study is to determine whether exposure to a four-phase “preconception to early childhood” intervention can (1) reduce child overweight and obese states, (2) improve cardiometabolic risk factors, (3) enhance child development and school readiness by age 5 years, and (4) positively impact parental outcomes when the child is aged 5 years.
Who can participate?
Women planning to get pregnant within the next 3 years, their partners and when possible the first “sibling child”.
What does the study involve?
HeLTI-Canada is a multicentre randomized controlled trial that will include 5230 women planning to get pregnant within the next 3 years. We will recruit 786 nulliparous (no children) and 4444 multiparous women, their partners and when possible the first “sibling child”. These women will be randomly allocated in a 1:1 ratio to the 4-phase preconception-lifecourse intervention or to the control arm. Participants will be recruited all across Canada. The intervention will be provided in 4 phases: (1) preconception, (2) pregnancy, (3) infancy [0-2 years], and (4) early childhood [3-5 years]. For intervention participants, two core strategies will be used throughout the 4 phases: (1) public health nurse collaborative care and (2) individualized e-health cloud platform that includes web-based resources and multi-platform interventions. All women will be assigned a trial public health nurse (t-PHN), hired and trained by the team, to provide telephone-based collaborative care starting within a week of randomization. The activities provided will include the standard criteria for collaborative care: (1) individual assessment; (2) structured management plan; and (3) scheduled follow-up. Part I: Telephone Assessment. At the beginning of each of the 4 intervention phases, the assigned t-PHN will telephone the woman, complete an assessment based on phase goals, and identify potential risks. Part II: Structured Management Plan. As in most collaborative care interventions, the t-PHN’s role will be to: (1) educate the woman and her partner (if applicable) about identified risks and management options; (2) assess management barriers and preferences; and (3) coordinate a management plan with appropriate public health, primary care, and community services. For example, if a woman requires breastfeeding assistance, local supports will be identified. The t-PHN will follow-up on the referrals to promote uptake. Local public health nurses may subsequently refer participants to other community services or programs as necessary and this will be tracked. Part III: Scheduled Follow-Up. The t-PHN will telephone participants every 2 weeks to: (1) review management plans; (2) monitor management initiation and adherence; and (3) track targeted behaviours (e.g., nutrition, physical activity) or symptomatology (e.g., depression). Telephone contacts will last between 15 to 45 minutes based on individual needs. This monitoring will facilitate early detection of risk that can be targeted. Based on behaviour modification and reduced risk, the participant will move from the ‘active phase’ of the intervention to the ‘continuation phase’. During this phase, participants will receive telephone follow-up every 2 months until completion of the phase (e.g., participant becomes pregnant, gives birth, or infant moves into early childhood phase at age 3 years). All participants have the option to proactively call the t-PHN as needed. Women allocated to the control group will have access to standard care provided to all women from preconception to early childhood (child age 5) but they will not receive the preconception-lifecourse intervention. Participants in the control arm will be provided access to standard care and an e-health cloud platform that includes web-based resources related to injury prevention.
All participants will be asked to complete web-based questionnaires and clinical data at baseline and at scheduled intervals during the preconception, pregnancy and postpartum periods. Biospecimen data will be collected from a sub-sample of participants.
What are the possible benefits and risks of participating?
Women and their partners in both groups will have access to all standard care preconceptionally and across the perinatal period until early childhood. Diverse safety protocols have been developed. For example, participants who screen positive for self-harm will be further assessed and referred for care as needed. We will also follow a protocol for infant/child harm if we suspect any potential child abuse/neglect. Adverse events will be reported to and monitored by a data safety and monitoring board.
Where is the study run from?
Mount Sinai Hospital (Sinai Health), Toronto, Canada
When is the study starting and how long is it expected to run for?
July 2017 until December 2032
Who is funding the study?
Canadian Institutes of Health Research
Who is the main contact?
Dr. Cindy-Lee Dennis, Principal investigator.
cindylee.dennis@utoronto.ca
Contact information
Public
St. Michael's Hospital
30 Bond Street
Toronto
M5B 1W8
Canada
| 0000-0002-8887-5359 | |
| Phone | +1 416 864 6060 ext. 77057 |
| FerreiraAlv@smh.ca |
Scientific
University of Toronto
Faculty of Nursing
Room 280
155 College Street
Toronto
M5T 1P8
Canada
| 0000-0002-0135-7242 | |
| Phone | +1 416 946 8608 |
| cindylee.dennis@utoronto.ca |
Scientific
Peter Gilgan Centre for Research and Learning
SickKids Research Institute
686 Bay Street 10-9709
Toronto
M5G 0A4
Canada
| 0000-0003-0308-8645 | |
| Phone | +1 416 813 4930 |
| catherine.birken@sickkids.ca |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomized controlled multicenter trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | A preconception-early childhood telephone-based intervention with tailored e-health resources for women and their partners to optimise growth and development among children in Canada: A Healthy Life Trajectory Initiative (HeLTI-Canada) |
| Study acronym | HeLTI Canada |
| Study objectives | Among women (and their partners) planning a pregnancy, when compared to usual care, we hypothesize that the complete 4-phase “preconception to early childhood” life-course intervention will: 1. Reduce child overweight and obese states 2. Improve cardiometabolic risk factors 3. Enhance child development and school readiness by age 5 years (objective 1) 4. Positively impact parental outcomes when the child is aged 5 years (objective 2) |
| Ethics approval(s) | 1. Approved 12/01/2024, Lunenfeld-Tanenbaum Research Institute ( Sinai Health ) (700 University Avenue, Suite 8-600, Toronto, M5G 1Z5, Canada; 416-586-4875; REB.Office@sinaihealth.ca), ref: CTO 1776 2. Approved 14/01/2020, St. Michael's Hospital (30 Bond St, Toronto, Toronto, M5B 1W8, Canada; 416-864- 6060; researchethics@unityheath.to), ref: CTO 1776 |
| Health condition(s) or problem(s) studied | Obesity among children |
| Intervention | Current interventions, as of 17/06/2024: The intervention will be provided in 4 phases: (1) preconception, (2) pregnancy, (3) infancy [0-2 years], and (4) early childhood [3-5 years]. Each phase has time-sensitive goals based on child obesity risk factor meta-analyses and comparable to the international HeLTI studies. Participants assigned to the intervention arm will receive (1) public health nurse collaborative care and (2) access to an individualized e-health cloud platform that includes web-based resources and multi-platform interventions pertaining to preconception risk factors. We will combine these two different strategies to provide a comprehensive, personalized intervention from preconception to early childhood. Participants assigned to the control arm will receive access to an e-health cloud platform that includes web-based resources that pertain to safety only. The study will be conducted with 5230 women planning (intending) to get pregnant. We will recruit 786 nulliparous (15%) and 4444 multiparous (85%) women, their partners, and, when possible, the first “sibling child.” These women will be randomly allocated in a 1:1 ratio to the 4-phase preconception-life-course intervention or to usual care, using web-based central randomization. An “index child” conceived after randomization (n = 3660; 70%) will be followed until age 5 years and assessed for the primary and secondary outcomes. Pregnancy, infancy (age 2 years), and parental outcomes will also be assessed. In addition, among the 4444 primiparous women planning their second pregnancy, their preceding first child (called the “sibling child”), aged 6 months (eligible range 3 to 12 months) when the mother is randomized, will also be followed until age 5 years. This concurrent randomized trial will compare those intervention phases specific to infancy and early childhood vs. usual care in these “sibling” children. This added component will allow us to estimate the additional effect of the preconception + pregnancy phases of the intervention (which are only received by the index child), beyond that of the infancy + early childhood phases of the intervention (which are also received by the sibling child), while fully preserving randomization. _____ Previous interventions: The intervention will be provided in 4 phases: (1) preconception, (2) pregnancy, (3) infancy [0-2 years], and (4) early childhood [3-5 years]. Each phase has time-sensitive goals based on child obesity risk factor meta-analyses and comparable to the international HeLTI studies. Participants assigned to the intervention arm will receive (1) public health nurse collaborative care and (2) access to an individualized e-health cloud platform that includes web-based resources and multi-platform interventions pertaining to preconception risk factors. We will combine these two different strategies to provide a comprehensive, personalized intervention from preconception to early childhood. Participants assigned to the control arm will receive access to an e-health cloud platform that includes web-based resources that pertain to safety only. The study will be conducted with 5230 women planning (intending) to get pregnant. We will recruit 786 nulliparous (15%) and 4444 primiparous (85%) women, their partners, and, when possible, the first “sibling child.” These women will be randomly allocated in a 1:1 ratio to the 4-phase preconception-life-course intervention or to usual care, using web-based central randomization. An “index child” conceived after randomization (n = 3660; 70%) will be followed until age 5 years and assessed for the primary and secondary outcomes. Pregnancy, infancy (age 2 years), and parental outcomes will also be assessed. In addition, among the 4444 primiparous women planning their second pregnancy, their preceding first child (called the “sibling child”), aged 6 months (eligible range 3 to 12 months) when the mother is randomized, will also be followed until age 5 years. This concurrent randomized trial will compare those intervention phases specific to infancy and early childhood vs. usual care in these “sibling” children. This added component will allow us to estimate the additional effect of the preconception + pregnancy phases of the intervention (which are only received by the index child), beyond that of the infancy + early childhood phases of the intervention (which are also received by the sibling child), while fully preserving randomization. |
| Intervention type | Behavioural |
| Primary outcome measure(s) |
Child overweight and obesity rate (at age 5 years) measured as the proportion of children with BMI >85 percentile using the WHO growth reference ranges, by sex, at age 5 years. Height/length and weight will be measured using standardized instruments and procedures. |
| Key secondary outcome measure(s) |
Child outcomes (all at age 5 years): |
| Completion date | 01/12/2032 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 5230 |
| Key inclusion criteria | Current inclusion criteria as of 17/06/2024: 1. Non-pregnant female 2. No child OR a child between 3-12 months postpartum 3. Planning a pregnancy in the next 3 years 4. Understands written English, 5. Resides in Canada ______ Previous inclusion criteria: 1. Non-pregnant female 2. No child OR one child between 3-12 months postpartum 3. Planning a pregnancy in the next 3 years 4. Understands written English, 5. Resides in Ontario or Alberta |
| Key exclusion criteria | Current exclusion criteria as of 17/06/2024: 1. Type 1 diabetes _____ Previous exclusion criteria: 1. Type 1 diabetes 2. Two or more children |
| Date of first enrolment | 14/01/2021 |
| Date of final enrolment | 01/12/2024 |
Locations
Countries of recruitment
- Canada
Study participating centre
Toronto
M5G 1X5
Canada
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | The Healthy Life Trajectories Initiative (HeLTI) was launched as a joint initiative between the Canadian Institute of Health Research, the Department of Biotechnology of India, the South African Medical Research Council, the National Science Foundation of China and the World Health Organisation. Data sharing and access arrangements are included in the overall HeLTI governance document. The HeLTI consortium is in the process of establishing a Data Access Portal though which investigators can view and request access to data/biospecimens within individual HeLTI country or multiple country datasets. Data access will follow country-specific guidelines and is expected to require submission of a detailed research plan (including study rationale, hypothesis, analytic methodologies and funding support to complete the study /analyses). Once the study is completed the researchers will be required to submit all analytical and derived data with metadata to be integrated into the HeLTI country datasets, so that it is available to other researchers. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Other publications | Fidelity assessment protocol | 07/04/2023 | 11/04/2023 | Yes | No |
| Other publications | Governance model for the HeLTI Consortium | 16/05/2023 | 17/05/2023 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
17/06/2024: The following changes were made to the trial record:
1. The ethics approval was added.
2. The overall end date was changed from 30/06/2027 to 01/12/2032.
3. The interventions were changed.
4. The study website was changed from https://helti.org/ to https://www.helticanada.com/.
5. Link to participant information sheet added.
6. The inclusion criteria were changed.
7. The exclusion criteria were changed.
8. The recruitment start date was changed from 01/05/2019 to 14/01/2021.
9. The recruitment end date was changed from 01/05/2022 to 01/12/2024.
10. The study participating centre Applied Health Research Centre and Li Ka Shing Knowledge Institute at St Michael's Hospital was changed to Mount Sinai Hospital (Sinai Health)
11. The participant level data sharing statement was added.
12. The intention to publish date was changed from 01/08/2019 to 01/12/2032.
13. The plain English summary was updated to reflect these changes.
17/05/2023: Publication reference added.
11/04/2023: The following changes have been made:
1. Publication reference added.
2. The study website has been added.
10/06/2019: Internal review.
07/06/2019: Internal review.
26/02/2019: Trial’s existence confirmed by Canadian Institutes of Health Research